Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Design of Polymeric Nanocapsules for Intranasal Vaccination against Mycobacterium Tuberculosis: Influence of the Polymeric Shell and Antigen Positioning

  • Diego González, Lara
  • Crecente Campo, José
  • Paul, Matthew John
  • Singh, Mahavir
  • Reljic, Rajko
  • Alonso Fernández, María José
  • González Fernández, África
  • Simón Vázquez, Rosana
Tuberculosis (TB) is the leading cause of death from a single infectious microorganism and Bacillus Calmette Guerin (BCG), the only authorized vaccine, does not confer protection against pulmonary TB. Based on the hypothesis that mucosal protection could help to prevent the infection at the site of entrance, the objective of this work was to develop an intranasal vaccine against Mycobacterium tuberculosis (Mtb), the microorganism that causes TB. Our approach consisted of the use of polymeric nanocapsules (NCs) with an oily core and a polymer shell made of chitosan (CS) or inulin/polyarginine (INU/pArg). The immunostimulant Imiquimod, a Toll-like receptor-7 (TLR-7) agonist, was encapsulated in the oily core and a fusion protein, formed by two antigens of Mtb, was absorbed either onto the NC surface (CS:Ag and INU:pArg:Ag) or between two polymer layers (INU:Ag:pArg) in order to assess the influence of the antigen positioning on the immune response. Although CS NCs were more immunostimulant than the INU/pArg NCs in vitro, the in vivo experiments showed that INU:pArg:Ag NCs were the only prototype inducing an adequate immunoglobulin A (IgA) response. Moreover, a previous immunization with BCG increased the immune response for CS NCs but, conversely, decreased for INU/pArg NCs. Further optimization of the antigen and the vaccination regime could provide an efficacious vaccine, using the INU:pArg:Ag NC prototype as nanocarrier
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Design of polymeric nanocapsules for intranasal vaccination against mycobacterium tuberculosis: influence of the polymeric shell and antigen positioning

  • Diego González, Lara
  • Crecente Campo, José
  • Paul, Matthew John
  • Singh, Mahavir
  • Reljic, Rajko
  • Alonso, María José
  • González Fernández, Maria Africa
  • Simón Vázquez, Rosana
Tuberculosis (TB) is the leading cause of death from a single infectious microorganism and Bacillus Calmette Guerin (BCG), the only authorized vaccine, does not confer protection against pulmonary TB. Based on the hypothesis that mucosal protection could help to prevent the infection at the site of entrance, the objective of this work was to develop an intranasal vaccine against Mycobacterium tuberculosis (Mtb), the microorganism that causes TB. Our approach consisted of the use of polymeric nanocapsules (NCs) with an oily core and a polymer shell made of chitosan (CS) or inulin/polyarginine (INU/pArg). The immunostimulant Imiquimod, a Toll-like receptor-7 (TLR-7) agonist, was encapsulated in the oily core and a fusion protein, formed by two antigens of Mtb, was absorbed either onto the NC surface (CS:Ag and INU:pArg:Ag) or between two polymer layers (INU:Ag:pArg) in order to assess the influence of the antigen positioning on the immune response. Although CS NCs were more immunostimulant than the INU/pArg NCs in vitro, the in vivo experiments showed that INU:pArg:Ag NCs were the only prototype inducing an adequate immunoglobulin A (IgA) response. Moreover, a previous immunization with BCG increased the immune response for CS NCs but, conversely, decreased for INU/pArg NCs. Further optimization of the antigen and the vaccination regime could provide an efficacious vaccine, using the INU:pArg:Ag NC prototype as nanocarrier., Xunta de Galicia | Ref. ED431C 2016/041, Xunta de Galicia | Ref. ED431C 2017/09, Xunta de Galicia | Ref. ED431G2019/06
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Contribution and future of high-throughput transcriptomics in battling tuberculosis

  • Martinez Perez, Amparo
  • Estévez Martínez, Olivia
  • González Fernández, Maria Africa
While Tuberculosis (TB) infection remains a serious challenge worldwide, big data and “omic” approaches have greatly contributed to the understanding of the disease. Transcriptomics have been used to tackle a wide variety of queries including diagnosis, treatment evolution, latency and reactivation, novel target discovery, vaccine response or biomarkers of protection. Although a powerful tool, the elevated cost and difficulties in data interpretation may hinder transcriptomics complete potential. Technology evolution and collaborative efforts among multidisciplinary groups might be key in its exploitation. Here, we discuss the main fields explored in TB using transcriptomics, and identify the challenges that need to be addressed for a real implementation in TB diagnosis, prevention and therapy, Xunta de Galicia | Ref. ED431C 2016/041, Xunta de Galicia | Ref. ED481A-2018/230, European Commission | Ref. H2020, n. 643558
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

An RNA-seq based machine learning approach identifies latent tuberculosis patients with an active tuberculosis profile

  • Estévez Martínez, Olivia
  • Anibarro Garcia, Luis
  • Garet Fernández, María Elina
  • Pallares, Ángeles
  • Barcia, Laura
  • Calviño, Laura
  • Maueia, Cremildo
  • Mussá, Tufária
  • Fernández Riverola, Florentino
  • González Peña, Daniel
  • Reboiro Jato, Miguel
  • López Fernández, Hugo
  • Fonseca, Nuno A.
  • Reljic, Rajko
  • González Fernández, Maria Africa
A better understanding of the response against Tuberculosis (TB) infection is required to accurately identify the individuals with an active or a latent TB infection (LTBI) and also those LTBI patients at higher risk of developing active TB. In this work, we have used the information obtained from studying the gene expression profile of active TB patients and their infected –LTBI- or uninfected –NoTBI- contacts, recruited in Spain and Mozambique, to build a class-prediction model that identifies individuals with a TB infection profile. Following this approach, we have identified several genes and metabolic pathways that provide important information of the immune mechanisms triggered against TB infection. As a novelty of our work, a combination of this class-prediction model and the direct measurement of different immunological parameters, was used to identify a subset of LTBI contacts (called TB-like) whose transcriptional and immunological profiles are suggestive of infection with a higher probability of developing active TB. Validation of this novel approach to identifying LTBI individuals with the highest risk of active TB disease merits further longitudinal studies on larger cohorts in TB endemic areas., Xunta de Galicia | Ref. ED431C 2016/041, Ministerio de Educación, Cultura y Deporte | Ref. FPU13/03026
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Tesis doctoral (DoctoralThesis)

Nanovacunas y lipoplexos para prevención y terapia, Nanovacinas e lipoplexos para prevención e terapia, Nanovaccines and lipoplexes for prevention and therapy

  • Diego González, Lara
En la actualidad, el uso de los nanomateriales en el campo de la Nanomedicina se ha visto en auge, y una de las aplicaciones con más perspectivas de futuro es el desarrollo de vacunas. El cáncer es una de las principales causas de mortalidad en el mundo. Concretamente, el cáncer de páncreas es el más mortífero, con una supervivencia de entre un 14% (estadio IA) hasta un 1% (estadio IV) a los 5 años del diagnóstico. Una característica importante de este tumor es que presenta una mutación en la proteína K-RAS, generalmente en la posición 12. Además, ciertas moléculas relacionadas con esta proteína se encuentran sobreexpresadas, como pueden ser las moléculas de señalización y activación FOSL-1 y YAP. Por tanto, el objetivo principal de esta tesis es obtener nuevas vacunas terapéuticas frente al cáncer pancreático, basadas en nanoestructuras. La vacuna se dirigirá contra la proteína K-RAS mutada y, se intentará potenciar su efecto mediante el bloqueo de las moléculas FOSL-1 y YAP utilizando siRNA. Para el desarrollo de la vacuna se sintetizarán nanoestructuras, en cuya superficie, o bajo su cubierta polimérica, se localizará el antígeno contra el cual se quiere generar la respuesta inmunitaria y que se basa en péptidos mutados en la posición 12 de la proteína K-RAS. Asimismo, para lograr el silenciamiento de las moléculas FOSL-1 y YAP se procederá a la encapsulación de los siRNA en nanoestructuras para que éstas sean liberadas de forma dirigida en las células tumorales. Una vez sintetizadas, las nanoestructuras serán caracterizadas, y se llevarán a cabo estudios de estabilidad temporal, de biocompatibilidad y de activación celular. Los prototipos más prometedores se testarán en ratones C57BL-6 implantados con células de cáncer de páncreas con la mutación de K-RAS. Se obtendrán muestras del tumor y de diferentes órganos, con las cuales se realizarán estudios histológicos y celulares para determinar la eficacia terapéutica, la respuesta inmunitaria a la vacuna y la posible toxicidad de los tratamientos. Este trabajo de tesis se llevará a cabo en el Centro de Investigaciones Biomédicas (CINBIO) y su tiempo previsto es de 3 años. Los resultados se presentarán tanto en congresos nacionales e internacionales como en revistas científicas. Destacar que, este trabajo también podría dar lugar a alguna patente., Na actualidade, o emprego dos nanomateriais no campo da Nanomedicina veuse en auxe, e unha das aplicacións con máis perspectivas de futuro é o desenvolvemento de vacinas. O cancro é unha das principais causas de mortalidade no mundo. Concretamente, o cancro de páncreas é máis mortífero, cunha supervivencia de entre un 14% (estadio IA) ata un 1% (estadio IV) aos 5 anos do diagnóstico. Unha característica importante deste tumor é que presenta unha mutación na proteína K-RAS, xeralmente na posición 12. Ademais, certas moléculas relacionadas con esta proteína atópanse sobreexpresadas, como poden ser as moléculas de sinalización e activación FOSL-1 e YAP. Polo tanto, o obxectivo principal desta tese é obter novas vacinas terapéuticas fronte ó cancro pancreático, baseadas en nanoestructuras. A vacina dirixirase contra a proteína K-RAS mutada e, intentarase potenciar o seu efecto mediante o bloqueo das moléculas FOSL-1 e YAP utilizando siRNA. Para o desenvolvemento da vacina sintetizaranse nanoestructuras, en cuxa superficie, ou baixo a súa cuberta polimérica, localizarase o antíxeno contra o cal quere xerarse a resposta inmunitaria e que se basea en péptidos mutados na posición 12 da proteína K-RAS. Así mesmo, para lograr o silenciamento das moléculas FOSL-1 e YAP procederase a encapsulación dos siRNA en nanoestructuras para que estas sexan liberadas de forma dirixida nas células tumorais. Unha vez sintetizadas, as nanoestructuras caracterizaranse, e se farán estudos de estabilidade no tempo, de biocompatibilidade e de activación celular. Os prototipos máis prometedores serán testados en ratos C57BL-6 implantados con células de cancro de páncreas coa mutación de K-RAS. Obteranse mostras do tumor e de diferentes órganos, coas cales realizaranse estudos histolóxicos e celulares para determinar a eficacia terapéutica, a resposta inmunitaria á vacina e a posible toxicidade dos tratamentos. Este traballo de tese levarase a cabo no Centro de Investigacións Biomédicas (CINBIO) e o seu tempo previsto é de 3 anos. Os resultados obtidos presentaranse tanto en congresos nacionais e internacionais como en revistas científicas. Destacar que, este traballo tamén podería dar lugar a algunha patente., Nowadays, the use of the nanomaterials in the field of the Nanomedicine has increased, and one of the applications with more perspectives is the development of vaccines. Cancer is one of the main causes of mortality worldwide. Specifically, pancreatic cancer is the second deadliest malignancy, with a five-years survival rate of 14% (stage IA) down to 1% (stage IV) after diagnosis. An important feature of this tumour is a mutation in the K-RAS protein, generally at position 12. In addition, some molecules related to this protein, such as the signalling and activation molecules of tumour cells: FOSL-1 and YAP are overexpressed. Therefore, the main aim of this thesis is to obtain new therapeutic vaccines against pancreatic cancer, based on nanostructures. The vaccine will be directed against the mutated K-RAS protein, and FOSL-1 and YAP will be blocked using siRNA to enhance the antitumor effect. For the development of the vaccine, nanostructures will be synthesized. Different peptides of the mutated K-RAS protein at position 12 will be tested as potential antigens. They will be located on the surface of the nanostructure, or under the polymeric shell. Likewise, the encapsulation of siRNA in nanostructures targeted to the tumour cells will be carried out to achieve the silencing of the FOSL-1 and YAP molecules. After the synthesis of the nanostructures, the physico-chemical and stability characterization will be carried out. In addition, the biocompatibility and cell activation will be studied in different cell types. The most promising prototypes will be tested in C57BL-6 mice implanted with K-RAS mutated pancreatic cancer cells. The tumour and different organs will be collected for histological and cellular studies to determine the therapeutic efficacy, the immune response to the vaccine and the potential toxicity of the treatments. This thesis project will be carried out at the Center for Biomedical Research (CINBIO) and the expected duration is 3 years. The results will be presented in national and international congresses, as well as in scientific journals. The results of this project could also lead to some patent., Agencia Estatal de Investigación | Ref. BIO2017-84974-R, Xunta de Galicia | Ref. ED431C 2020/02, Xunta de Galicia | Ref. ED481A 2018/294
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Tesis doctoral (DoctoralThesis)

Characterization of the immune response driven by novel nanoparticle-based vaccines for tuberculosis, Caracterización da resposta inmune inducida por novas vacinas contra a tuberculose baseadas en nanopartículas, Caracterización de la respuesta inmunitaria inducida por nuevas vacunas contra la tuberculosis basadas en nanopartículas

  • Martinez Perez, Amparo
Lung diseases are a common and diverse group of illnesses that represent a health problem affecting millions of people worldwide. The microenvironment and the immune system in the lung are very important but they are also the most challenging immunological dilemma for the host. On one hand, lung location and function are constantly exposed to pathogens; but on the other hand should be sterile and preserve lung homeostasis through the balance between tolerance and inflammation. For this reason is extremely important to characterize and understand the mechanisms and populations involved in a protective immune response, and find better targets to design vaccines. The aim of this project is to define and understand the immunological profiles that correlate with greater protection generated by preventive and therapeutic vaccines in the lung. Preventive vaccines are generally administered to healthy individuals to prevent or ameliorate infectious diseases, but therapeutic cancer vaccines are administrated once the individual has already developed the disease to strength patient's own immune responses. We will focus on two different lung diseases: an infection caused by a bacteria and lung cancer. To study a bacterial infection, we will use as a model Mycobacterium tuberculosis (Mtb), responsible for Tuberculosis (TB). TB is a serious global health problem and the only licensed vaccine against TB is "Mycobacterium bovis Bacille Calmette-Guérin" (BCG). But BCG has a poor efficacy. To achieve a better understanding of the type of immune responses that confer protection, we will use a mouse model to assess the changes in the immune system produced in the lung by vaccines and in response to Mtb infection. Lung cancer is a devastating disease and a major therapeutic burden with poor survival rates. Cancer cells have been in the focus of the research, but the importance of the immune system is becoming more important. Syngenic murine models entailing the injection of immunological compatible cancer cells in immunocompetent mice will allow us to study of the modulation of the immune system performed by cancer cells. Moreover, we will use therapeutic vaccines against tumor cells to activate anti-tumor T cells to recognize and destroy the tumor, increasing the effectiveness when used alone or in combination with conventional therapies. In both approaches, the immune cell populations present in the bronchoalverolar lavage (BAL) and in the lung parenchyma, and the ones induced by the different experimental conditions, will be analyzed and characterized by flow cytometry and ELISA. Also, cells will be obtained to perform proteomic and gene expression profiles to better define the pathways with impact in controlling infection or cancer cells. The outputs generated by our research would lead in the future to a more rational design of protective prophylactic and therapeutic vaccines against lung diseases., Las enfermedades pulmonares son un grupo diverso de enfermedades que afectan a millones de personas en todo el mundo. El microambiente y el sistema inmunitario en el pulmón son muy importantes a la vez que suponen un dilema para el huésped. Por un lado, por su ubicación y función, el pulmón está constantemente expuesto a patógenos; por otro lado debe ser estéril y preservar la homeostasis a través del equilibrio entre tolerancia e inflamación. Por ello es extremadamente importante caracterizar y comprender los mecanismos y las poblaciones involucradas en una respuesta inmunitaria protectora, y encontrar mejores dianas para diseñar vacunas. El objetivo de este proyecto es definir y comprender los perfiles inmunitarios que correlacionan con una mayor protección generada por vacunas preventivas y terapéuticas en pulmón. Las vacunas preventivas se administran a individuos sanos para prevenir o mejorar enfermedades infecciosas, mientras que las vacunas terapéuticas contra el cáncer se administran, para fortalecer la propia respuesta inmunitaria del paciente. Nos centraremos en dos enfermedades pulmonares: una infección causada por una bacteria y cáncer de pulmón. Para estudiar la infección bacteriana, utilizaremos como modelo Mycobacterium tuberculosis (Mtb), responsable de la tuberculosis. La tuberculosis es un grave problema de salud mundial. La única vacuna autorizada contra ella es "Mycobacterium bovis Bacille Calmette-Guérin" (BCG), que tiene una baja eficacia. Para comprender mejor el tipo de respuestas inmunológicas que confieren protección, utilizaremos un modelo de ratón para evaluar los cambios en el sistema inmunitario producidos por diferentes vacunas y la infección de Mtb en el pulmón. El cáncer de pulmón es una enfermedad devastadora, con una carga terapéutica importante y baja tasa de supervivencia. La investigación se ha centrado en las células tumorales, pero el sistema inmunitario se está volviendo cada vez más importante. Los modelos murinos sinogénicos permiten la inyección de células cancerosas inmunológicamente compatibles en ratones inmunocompetentes para estudiar la modulación del sistema inmunitario por las células tumorales. Además, utilizaremos vacunas terapéuticas para activar las células T a fin de que reconozcan y destruyan el tumor, aumentando su eficacia solas o en combinación con terapias convencionales. En ambos casos, las poblaciones celulares inmunitarias presentes en el lavado broncoalverolar y el parénquima pulmonar en las diferentes condiciones experimentales serán analizadas y caracterizadas por citometría de flujo y ELISA. Se obtendrán además células para estudios proteómicos y de expresión génica, para definir mejor las vías implicadas en el control de la infección o de las células cancerosas. Los resultados obtenidos podrían conducir en el futuro a un diseño más racional de vacunas profilácticas y terapéuticas contra enfermedades pulmonares., As enfermidades pulmonares son un grupo diverso de enfermidades que afectan a millóns de persoas en todo o mundo. O microambiente e o sistema inmunitario nos pulmóns son moi importantes ao mesmo tempo que representan un dilema para o hospedeiro. Por unha banda, debido á súa localización e función, o pulmón está constantemente exposto a patóxenos; por outra banda, debe ser estéril e preservar a homeostase a través do equilibrio entre tolerancia e inflamación. Por iso, é moi importante caracterizar e comprender os mecanismos e poboacións implicados nunha resposta inmune protectora e atopar mellores obxectivos para o deseño de vacinas. O obxectivo deste proxecto é definir e comprender os perfís inmunolóxicos que se correlacionan con maior protección xerada por vacinas preventivas e terapéuticas no pulmón. As vacinas preventivas son xeralmente administradas a individuos sans para previr ou mellorar doenzas infecciosas, mentres que as vacinas terapéuticas contra o cancro son administradas unha vez o individuo desenvolve a enfermidade para fortalecer a súa resposta inmunitaria. Centrarémonos en dúas enfermidades pulmonares: unha infección bacteriana e cancro de pulmón. Para estudar unha infección bacteriana, usaremos como modelo Mycobacterium tuberculosis (MTB), responsable da tuberculose (TB), un grave problema de saúde global. A única vacina con licenza actualmente é "Mycobacterium bovis Bacille Calmette-Guérin" (BCG), que ten unha baixa eficacia. Para entender mellor o tipo de respostas inmunolóxicas que confiran protección, usaremos un modelo de rato para avaliar cambios no sistema inmunitario causadas por vacinas e infección por MTB no pulmón. O cancro de pulmón é unha enfermidade devastadora, cunha importante carga terapéutica e baixa taxa de supervivencia. As células tumorais foron o foco da investigación, pero o sistema inmunolóxico é cada vez máis importante. Os modelos murinos sinxénicos, que inclúen a inxección de células de cancro imunolóxicamente compatibles en ratos inmunocompetentes, permítennos estudar a modulación do sistema inmunitario por células tumorais. Ademáis, utilizaremos vacinas terapéuticas para activar as células T que recoñezan e destrúan o tumor, aumentando a súa eficacia cando se usa só ou en combinación con terapias convencionais. En ambos casos, as poboacións de células inmunitarias presentes no lavado broncoalverolar e o parénquima pulmonar nas diferentes condicións experimentais analizaranse e caracterízanse por citometría de fluxo e ELISA. As células tamén se obterán para estudos proteómicos e de expresión xénica, para definir mellor as vías implicadas no control da infección ou as células cancerosas. Os resultados obtidos poderían levar no futuro a un deseño máis racional de vacinas profilácticas e terapéuticas contra as enfermidades pulmonares., Xunta de Galicia | Ref. ED431C 2016/041, Xunta de Galicia | Ref. ED431G 2019/06, Fundação para a Ciência e a Tecnologia | Ref. PTDC/SAU-INF/28463/2017, Fundação para a Ciência e a Tecnologia | Ref. UIDB/50026/2020, Fundação para a Ciência e a Tecnologia | Ref. UIDP/50026/2020
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection

  • Estévez Martínez, Olivia
  • Anibarro Garcia, Luis
  • Garet, Elina
  • Pallares, Ángeles
  • Pena Rodríguez, Alberto
  • Villaverde Taboada, Carlos Manuel Ramon
  • del Campo, Víctor
  • González Fernández, Maria Africa
In our work, we aim to identify new candidate host biomarkers to discriminate between active TB patients (n = 28), latent infection (LTBI; n = 27) and uninfected (NoTBI; n = 42) individuals. For that, active TB patients and their contacts were recruited that donated serum and saliva samples. A multiplex assay was performed to study the concentration of different cytokines, chemokines and growth factors. Proteins with significant differences between groups were selected and logistic regression and the area under the ROC curve (AUC) was used to assess the diagnostic accuracy. The best marker combinations that discriminate active TB from NoTBI contacts were [IP-10 + IL-7] in serum and [Fractalkine + IP-10 + IL-1α + VEGF] in saliva. Best discrimination between active TB and LTBI was achieved using [IP-10 + BCA-1] in serum (AUC = 0.83) and IP-10 in saliva (p = 0.0007; AUC = 0.78). The levels of TNFα (p = 0.003; AUC = 0.73) in serum and the combination of [Fractalkine+IL-12p40] (AUC = 0.83) in saliva, were able to differentiate between NoTBI and LTBI contacts. In conclusion, different individual and combined protein markers could help to discriminate between active TB and both uninfected and latently-infected contacts. The most promising ones include [IP-10 + IL-7], [IP-10 + BCA-1] and TNFα in serum and [Fractalkine + IP-10 + IL-1α + VEGF], IP-10 and [Fractalkine+IL-12p40] in saliva., Xunta de Galicia | Ref. ED431C 2016/041, Ministerio de Ecucación, Cultura y Deporte | Ref. FPU 13/03026
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Changes in the immune phenotype and gene expression profile driven by a novel tuberculosis nanovaccine: short and long-term post-immunization

  • Martinez Perez, Amparo
  • Igea Fernandez, Ana
  • Estévez Martínez, Olivia
  • Ferreira, Catarina M.
  • Torrado, Egídio
  • Castro, António Gil
  • Fernández, Carmen
  • Spetz, Anna Lena
  • Adam, Lucille
  • López González, Moisés
  • Singh, Mahavir
  • Reljic, Rajko
  • González Fernández, Maria Africa
Deciphering protection mechanisms against Mycobacterium tuberculosis (Mtb) remains a critical challenge for the development of new vaccines and therapies. We analyze the phenotypic and transcriptomic profile in lung of a novel tuberculosis (TB) nanoparticle-based boosting mucosal vaccine Nano-FP1, which combined to BCG priming conferred enhanced protection in mice challenged with low-dose Mtb. We analyzed the vaccine profile and efficacy at short (2 weeks), medium (7 weeks) and long term (11 weeks) post-vaccination, and compared it to ineffective Nano-FP2 vaccine. We observed several changes in the mouse lung environment by both nanovaccines, which are lost shortly after boosting. Additional boosting at long-term (14 weeks) recovered partially cell populations and transcriptomic profile, but not enough to enhance protection to infection. An increase in both total and resident memory CD4 and CD8 T cells, but no pro-inflammatory cytokine levels, were correlated with better protection. A unique gene expression pattern with differentially expressed genes revealed potential pathways associated to the immune defense against Mtb. Our findings provide an insight into the critical immune responses that need to be considered when assessing the effectiveness of a novel TB vaccine., Xunta de Galicia | Ref. ED431C 2016/041, Xunta de Galicia | Ref. ED431G2019/06, Xunta de Galicia | Ref. ED481A-2018/230, Fundação para a Ciência e a Tecnologia | Ref. PTDC/SAU-INF/28463/2017, Fundação para a Ciência e a Tecnologia | Ref. UIDB/50026/2020, Fundação para a Ciência e a Tecnologia | Ref. UIDP/50026/2020
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Multi-parameter flow cytometry immunophenotyping distinguishes different stages of tuberculosis infection

  • Estévez Martínez, Olivia
  • Anibarro Garcia, Luis
  • Garet Fernández, María Elina
  • Martinez Perez, Amparo
  • Pena, Alberto
  • Barcia, Laura
  • Peleteiro Olmedo, Mercedes
  • González Fernández, Maria Africa
Objectives: To identify new potential host biomarkers in blood to discriminate between active TB patients, uninfected (NoTBI) and latently infected contacts (LTBI). Methods: A blood cell count was performed to study parent leukocyte populations. Peripheral blood mononuclear cells (PBMCs) were isolated and a multi-parameter flow cytometry assay was conducted to study the distribution of basal and Mycobacterium tuberculosis (Mtb)-stimulated lymphocytes. Differences between groups and the area under the ROC curve (AUC) were investigated to assess the diagnostic accuracy. Results: Active TB patients presented higher Monocyte-to-lymphocyte and Neutrophil-to-lymphocyte ratios than LTBI and NoTBI contacts (p<0.0001; AUC>0.8). Lymphocyte subsets with differences (p >0.05; AUC >0.7) between active TB and both contact groups include the basal distribution of Th1/Th2 ratio, Th1-Th17, CD4+ Central Memory (TCM) or MAIT cells. Expression of CD154 is increased in Mtb-activated CD4+ TCM and Effector Memory T cells in active TB and LTBI compared to NoTBI. In CD4+T cells, expression of CD154 showed a higher accuracy than IFNγ to discriminate Mtb-specific activation. Conclusions: We identified different cell subsets with potential use in tuberculosis diagnosis. Among them, distribution of CD4 TCM cells and their expression of CD154 after Mtb-activation are the most promising candidates., Xunta de Galicia | Ref. ED431C 2016/041
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

High-resolution quantitative proteomics applied to the study of the specific protein signature in the sputum and saliva of active tuberculosis patients and their infected and uninfected contacts

  • Mateos, Jesús
  • Estévez, Olivia
  • González-Fernández, África
  • Anibarro, Luis
  • Pallarés, Ángeles
  • Reljic, Rajko
  • Gallardo, José Manuel
  • Medina, Isabel
  • Carrera, Mónica
12 pages, 10 figures, Our goal was to establish panels of protein biomarkers that are characteristic of patients with microbiologically confirmed pulmonary tuberculosis (TB) and their contacts, including latent TB-infected (LTBI) and uninfected patients. Since the first pathogen-host contact occurs in the oral and nasal passages the saliva and sputum were chosen as the biological fluids to be studied. Quantitative shotgun proteomics was performed using a LTQ-Orbitrap-Elite platform. For active TB patients, both fluids exhibited a specific accumulation of proteins that were related to complement activation, inflammation and modulation of immune response. In the saliva of TB patients, a decrease of in proteins related to glucose and lipid metabolism was detected. In contrast, the sputum of uninfected contacts presented a specific proteomic signature that was composed of proteins involved in the perception of bitter taste, defense against pathogens and innate immune response, suggesting that those are key events during the initial entry of the pathogen in the host, EMI-TB is a European Union Horizon 2020 funded action (Grant No 643558) that is focused on selecting and developing a novel vaccine candidate for tuberculosis (TB), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Serum proteomics of active tuberculosis patients and contacts reveals unique processes activated during Mycobacterium tuberculosis infection

  • Mateos, Jesús
  • Estévez, Olivia
  • González-Fernández, África
  • Anibarro, Luis
  • Pallarés, Ángeles
  • Reljic, Rajko
  • Mussá, Tufária
  • Gomes-Maueia, Cremildo
  • Nguilichane, Artur
  • Gallardo, José Manuel
  • Medina, Isabel
  • Carrera, Mónica
12 pages, 7 figures, 2 tables.-- This article is licensed under a Creative Commons Attribution 4.0 International License, Tuberculosis (TB) is the most lethal infection among infectious diseases. The specific aim of this study was to establish panels of serum protein biomarkers representative of active TB patients and their household contacts who were either infected (LTBI) or uninfected (EMI-TB Discovery Cohort, Pontevedra Region, Spain). A TMT (Tamdem mass tags) 10plex-based quantitative proteomics study was performed in quintuplicate containing a total of 15 individual serum samples per group. Peptides were analyzed in an LC-Orbitrap Elite platform, and raw data were processed using Proteome Discoverer 2.1. A total of 418 proteins were quantified. The specific protein signature of active TB patients was characterized by an accumulation of proteins related to complement activation, inflammation and modulation of immune response and also by a decrease of a small subset of proteins, including apolipoprotein A and serotransferrin, indicating the importance of lipid transport and iron assimilation in the progression of the disease. This signature was verified by the targeted measurement of selected candidates in a second cohort (EMI-TB Verification Cohort, Maputo Region, Mozambique) by ELISA and nephelometry techniques. These findings will aid our understanding of the complex metabolic processes associated with TB progression from LTBI to active disease, EMI-TB is a European Union Horizon2020-funded action (Grant No. 643558) focused on selecting and developing a novel vaccine candidate for TB, Peer reviewed